REDMOND, WA, APRIL 18, 2022 — Pattern Computer®, Inc. (PCI) is thrilled to announce that our combination drug candidates targeting High-grade Serous Ovarian Cancer (HGSOC) have moved into a preclinical in vitro study. The goal is to evaluate the effectiveness of these combination candidate therapies when compared to single agents. The study is a necessary precursor to subsequent animal studies.
HGSOC is the most lethal type of ovarian cancer, and lacks broadly effective treatment. While targeted therapy has emerged as a promising treatment for HGSOC, responses to these therapies are generally short-lived, due to the rapid emergence of drug resistance. Combining targeted drugs may improve overall clinical outcomes through overcoming or preventing the emergence of resistance, but the discovery of effective and rational drug combinations remains a daunting task.
Using PCI’s proprietary advanced mathematical computational platform, the Pattern Discovery Engine™ (PDE), we have identified 31 new high-quality candidates against HGSOC. PDE’s rational and systematic approach for combination drug discovery drastically reduces the number of test agents that are biologically evaluated before identifying novel, synergistic, and efficacious combination therapies.
PCI’s drug discovery efforts are currently focused on oncological malignancies. In addition to HGSOC, we are actively and aggressively applying our computational platform to identify potential treatments for other complex and intractable cancers including Triple-negative Breast Cancer, lung cancer, colorectal cancer, and metastatic Castration-Resistant Prostate Cancer.
“As we move our Triple-negative breast cancer candidates into their fifth round of test, we are very excited to have this set of 31 candidates moving into test for ovarian cancer. Moreover, we were able to improve calculational time for these drugs from about a year, to exactly six weeks.
These efforts are part of our larger StarBright Project, in which we have taken on the top five cancer killers. Our next announcement in this line will include exciting new genetic discoveries in colorectal cancer worldwide. We hope that by using this new mathematics to solve the most challenging problems in oncology, we can both save lives, and demonstrate a new, much faster and less risk-prone, path to drug discovery,” said Mark Anderson, CEO.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional COVID detection, biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
CONTACT: Brad Holtz – 301.529.9944 – bh@patterncomputer.com
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
Copyright © 2022 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, Dimensional Navigator, and ProSpectral are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.